TG Therapeutics has announced that the United States FDA has approved Briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS.
To learn more, please visit: mymsaa.org/news/fda-approve...
Blood Test for MS Activity Gets FDA Breakthrough Designation
New Shingles vaccine FDA approved
MS relapse indications
New to blogs, old in MS
